INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024 INBX stock results show that Inhibrx beat analyst estimates for earnings per share the first quarter of 2024.
INBX Stock Earnings: Inhibrx Biosciences Beats EPS for Q2 2024 INBX stock results show that Inhibrx Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
The NVDA Earnings Effect And What It Means For The Current Market Momentum Discover the confluence zone that will make or break the S&P 500 and the preliminary supply (early distribution) you need to be aware of.
Is The Stock Market Ready To Plunge? The Warning Signs Are Here... Find out how to spot the exhaustion of demand and the bearish analogue you could refer to to anticipate the down move.
Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx The company is buying Inhibrx, which is working on a treatment for alpha-1 antitrypsin deficiency.
French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected in Q2 2024.
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project Following the acquisition, New Inhibrx will continue to operate under the "Inhibrx" name, with Mark Lappe as Chairman and CEO.
$1.5M Bet On Domo? Check Out These 3 Stocks Insiders Are Buying Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.
Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Axcella Health Inc. (
NASDAQ: AXLA ) shares climbed 196% to $0.3335 after the company announced it was granted a patent for long COVID fatigue treatment.
PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.
Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating On Wednesday, Inhibrx stock now clears that desired 80-plus Relative Strength threshold, with a jump from 80 to 86 Wednesday.
$40 Million Bet On Inhibrx? 3 Stocks Insiders Are Buying Although US stocks closed slightly lower on Wednesday, there were a few notable insider trades.
Stocks Reverse Gains After ADP Report Wall Street's rally has come to a screeching halt, as Treasury yields tick higher once again.
Why Is Inhibrx (INBX) Stock Soaring 45% Today? Inhibrx received a vote of confidence from the Food and Drug Administration, skyrocketing the largely speculative INBX stock.
S&P 500 Rises 100 Points; Nasdaq Up 3% U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday.
Nasdaq Surges 350 Points; Crude Oil Rises Sharply U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 350 points on Tuesday.
